- Details
- In this conversation, Neha Vapiwala joins Alicia Morgans in a conversation on the ECOG-ACRIN EA8191 (INDICATE) phase III trial in progress. In patients with prostate cancer who experience biochemical recurrence, the ECOG-ACRIN EA8191 (INDICATE) trial examines whether patients without PET-detected lesions outside the pelvis benefit from the addition of apalutamide to standard salvage radiotherapy +...
|
- Details
- In this collaborative discussion, Alicia Morgans and Edward (Ted) Schaeffer examine the evolving guidelines for integrating PET imaging into the diagnosis and treatment of prostate cancer. Dr. Schaeffer emphasizes that these NCCN guidelines, which frequently adapt to new medical developments, act as a flexible framework rather than a rigid rulebook. The conversation explores the application of PSM...
|
- Details
- Alicia Morgans and Carsten-Henning Ohlmann discuss the SPARE trial, an exploratory phase two study involving chemo-naive metastatic castration-resistant prostate cancer patients. The trial compares the standard of care - ADT (Androgen Deprivation Therapy) plus abiraterone plus prednisone, versus abiraterone plus prednisone without the continuation of ADT. Preliminary results show no significant di...
|
- Details
- Neeraj Agarwal delves into two ground-breaking studies, discussing the importance of ctDNA testing and the clinical implications of SPOP mutations in patients with metastatic prostate cancer. The first study, led by Dr. Kim Chi, demonstrates that ctDNA testing is a viable alternative to invasive tissue testing, particularly in detecting BRCA and ATM mutations. CtDNA tests showed impressive sensiti...
|
- Details
- Amy Moran joins Alicia Morgans in a discussion on the mechanisms of immunotherapy resistance in prostate cancer patients, and how androgens or the androgen receptor (AR) contribute. Amy Moran received a Prostate Cancer Foundation Young Investigator Award for this research which aims to reveal how androgens and AR activity regulate human T cell function and immunotherapy resistance and may reveal n...
|
- Details
- Jeffrey Ross speaks about the evolution and application of liquid biopsies in cancer treatment, including in cases of advanced metastatic breast cancer and prostate cancer. Drawing from his experience with circulating cancer cells, he details the development of circulating DNA and emphasizes the importance of precision medicine and personalized care. He contrasts liquid biopsies with tissue biopsi...
|
- Details
- At the 29th Annual Prostate Cancer Foundation (PCF) Scientific Retreat Dr Saul Priceman joins Alicia Morgans in a discussion on clinic-ready CAR T cell therapies for Metastatic castrate-resistant prostate cancer (mCRPC) that can overcome the limitations of prior CAR T cell products for prostate cancer. Dr. Priceman highlights the role of PCF's funds in impacting these research efforts. The project...
|
- Details
- In a conversation with Alicia Morgans, Phillip Sutera discusses his work in metastasis-directed therapy (MDT). Dr. Sutera gives a brief overview of the background of the research discussing the association between prostate-specific membrane antigen (PSMA) response and radiographic-progression-free survival among patients treated with stereotactic ablative radiation therapy in oligometastatic castr...
|
- Details
- Samuel Washington shares insights from a study analyzing treatment practices for metastatic prostate cancer across the US. Utilizing a broad dataset provided by ConcertAI, a data warehouse company focusing on AI and big data, the team investigated patterns of doublet therapy administration among patients diagnosed with M1 disease. Dr. Washington and his team identified over 1,700 men across the co...
|
- Details
- Charles Ryan and Clayton Yates delve into the intricate landscape of health disparities and global health equity. Central to the discussion is Dr. Yates's groundbreaking work as principal investigator of MET-PAAM, studying the molecular mechanisms of tumor progression in metastatic prostate cancer among men of African descent. Dr. Yates provides insights into the unique BRCA2 gene variants found i...
|
